Matinas BioPharma Holdings (MTNB) Common Equity (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Common Equity of $3.0 million for Q1 2026, down 51.8% year-over-year from $6.3 million in Q1 2025, and down 37.43% quarter-over-quarter from $4.8 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Common Equity (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Common Equity for 14 consecutive years, with $3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 51.8% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $3.0 million (down 51.8% YoY), while the FY2025 annual figure was $4.8 million, down 36.36% from the prior year.
- Common Equity retreated to $3.0 million in Q1 2026 per MTNB's latest filing, from $4.8 million in the prior quarter.
- Across five years, Common Equity topped out at $47.7 million in Q1 2022 and bottomed at $3.0 million in Q1 2026.
- Historically, Common Equity has averaged $20.8 million across 5 years, with a median of $19.1 million in 2024.
- Annual changes were most pronounced in 2022 — Common Equity declined 28.36% — and 2024, when it plunged 60.56%.
- Matinas BioPharma Holdings' Common Equity stood at $36.6 million in 2022, then slumped by 47.47% to $19.2 million in 2023, then slumped by 60.56% to $7.6 million in 2024, then sank by 36.36% to $4.8 million in 2025, then slumped by 37.43% to $3.0 million in 2026.
- Business Quant data shows MTNB's Common Equity at $3.0 million in Q1 2026, $4.8 million in Q4 2025, and $6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 1.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.80 Mn |
| Mar 31, 2026 | 3.02 Mn |
| Dec 31, 2025 | 4.83 Mn |
| Sep 30, 2025 | 6.46 Mn |
| Jun 30, 2025 | 7.68 Mn |
| Mar 31, 2025 | 6.27 Mn |
| Dec 31, 2024 | 7.59 Mn |
| Sep 30, 2024 | 15.78 Mn |
| Jun 30, 2024 | 19.10 Mn |
| Mar 31, 2024 | 14.56 Mn |
| Dec 31, 2023 | 19.25 Mn |
| Sep 30, 2023 | 23.15 Mn |
| Jun 30, 2023 | 27.85 Mn |
| Mar 31, 2023 | 32.63 Mn |
| Dec 31, 2022 | 36.64 Mn |
| Sep 30, 2022 | 38.62 Mn |
| Jun 30, 2022 | 42.85 Mn |
| Mar 31, 2022 | 47.68 Mn |
| Dec 31, 2021 | 52.49 Mn |
| Sep 30, 2021 | 58.25 Mn |